Amlodipine
- amlodipine
- 88150-42-9
- Norvasc
- Amlocard
- Coroval
- Create:2005-03-25
- Modify:2025-01-11
- Amlodipine
- Amlodipine Besylate
- Amlodipine Maleate
- Amlodipine Maleate (1:1)
- Amlodipine, (+-)-Isomer
- Amlodipine, (+-)-Isomer, Maleate (1:1)
- Amlodipine, (R)-Isomer
- Amlodipine, (S)-Isomer, Maleate (1:1)
- Amlodis
- Amlor
- Astudal
- Istin
- Norvasc
- amlodipine
- 88150-42-9
- Norvasc
- Amlocard
- Coroval
- Lipinox
- Amlodipino
- Amlodipinum
- Amlodipine Free Base
- AMLODIPINE BASE
- Caduet
- Istin
- Amlodipinum [Latin]
- CHEBI:2668
- Amlodipine besilate
- 3-ethyl 5-methyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
- Amlodis
- UNII-1J444QC288
- HSDB 7079
- HGP0904
- UK-4834011
- HGP-0904
- Norvasc (TN)
- CKD-330 COMPONENT AMLODIPINE
- MFCD00864687
- 1J444QC288
- 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
- DTXSID7022596
- EC 425-820-1
- Amlodipino [Spanish]
- 88150-42-9 (free base)
- Amlodipinum (Latin)
- 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
- 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
- Amlodipine [INN:BAN]
- AMLODIPINE (MART.)
- AMLODIPINE [MART.]
- Racemic Amlodipine
- (RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
- 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
- 3-Ethyl-5-methyl (+-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat
- 3-Ethyl-5-methyl (+-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
- 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
- 3-O-ethyl 5-O-methyl 4-(2-chlorophenyl)-1-deuterio-2-[2-(dideuterioamino)ethoxymethyl]-6-methyl-4H-pyridine-3,5-dicarboxylate
- (R)-Amlodipine-d4
- 3,5-PYRIDINEDICARBOXYLIC ACID, 2-((2-AMINOETHOXY)METHYL)-4-(2-CHLOROPHENYL)-1,4-DIHYDRO-6-METHYL-, 3-ETHYL 5-METHYL ESTER, (+/-)-
- 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
- SR-05000001461
- NCGC00165957-04
- Amlodipine 100 microg/mL in Acetonitrile
- amlodipina
- (RS)-3-ethyl 5-methyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
- 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine
- 2-[2-aminoethoxymethyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine
- Amlodipine (Standard)
- amlodipine (NORVASC)
- AMLODIPINE [MI]
- Amlodipine (USP/INN)
- AMLODIPINE [INN]
- Spectrum2_000486
- Spectrum3_001004
- Spectrum4_001132
- Spectrum5_001550
- AMLODIPINE [VANDF]
- AMLODIPINE [WHO-DD]
- CHEMBL1491
- SCHEMBL26478
- BSPBio_002727
- KBioGR_001643
- MLS001401409
- AMLODIPINE [EMA EPAR]
- BIDD:GT0810
- SPBio_000351
- DTXCID302596
- GTPL6981
- AMLODIPINE [ORANGE BOOK]
- CHEMBL3211346
- CHEMBL3304444
- HY-B0317R
- KBio3_001947
- C08CA01
- Copalia (amlodipine + valsartan)
- Morphine Sulfate Pentahydrate USP
- BCPP000403
- HMS2052N03
- HMS2089H07
- HMS2231K08
- HMS3370G17
- HMS3394N03
- HMS3651I04
- HMS3713C10
- ALBB-027270
- BCP02420
- HY-B0317
- BDBM50088383
- s1905
- STL356053
- AKOS015843475
- AC-4535
- BCP9000295
- CCG-101157
- CCG-220414
- DB00381
- NC00407
- NCGC00165957-01
- NCGC00165957-02
- NCGC00165957-03
- NCGC00165957-05
- NCGC00165957-07
- 3-Ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
- AS-13747
- BA164164
- CPD000469198
- DA-56266
- O3-ethyl O5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
- PD003146
- PD033068
- SMR000469198
- SY104813
- DB-262294
- NS00000043
- SW220228-1
- C06825
- D07450
- EN300-708796
- AB01209618-01
- AB01274726-01
- AB01274726-02
- AB01274726_03
- AB01274726_04
- AB01274726_05
- Katerzia (amlodipine oral suspension, 1 mg/mL)
- Q411347
- Katerzia® (amlodipine oral suspension, 1 mg/mL)
- SR-05000001461-3
- SR-05000001461-4
- SR-05000001461-5
- BRD-A22032524-001-03-5
- BRD-A22032524-001-05-0
- BRD-A22032524-074-02-4
- BRD-A22032524-074-03-2
- BRD-A22032524-074-04-0
- BRD-A22032524-074-06-5
- BRD-A22032524-074-07-3
- BRD-A22032524-074-09-9
- 2-(2-aminoethoxy)methyl-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine
- 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methylester
- 2-[2-Aminoethoxymethyl]-3-ethoxycarbonyl-4-(2-chlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine
- 3,5-pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, benzene sulfonate
- 3-ETHYL 5-METHYL (+/-)-2-((2-AMINOETHOXY)METHYL)-4-(O-CHLOROPHENYL)-1,4-DIHYDRO-6-METHYL-3,5-PYRIDINEDICARBOXYLATE
- 3-Ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydro-3,5-pyridinedicarboxylate
- 3-Ethyl 5-methylester, (+-)-2-((2-aminoethoxy)methyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
- 3-Ethyl 5-methylester, (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
- 3-Ethyl-5-methyl (+-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylate
- 3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
- 3-ethyl5-methyl2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
238.0632 100
294.0898 52.72
208.0606 52.50
206.0366 47.79
377.1277 34.11
238.0634 100
294.089539 76.76
377.126556 54.20
240.059662 46.71
296.086182 26.79
238.0632 999
294.0898 526
208.0606 524
206.0366 477
377.1277 340
148 999
149 815
180 807
102 803
176 780
- Amlodipine Besylate (has salt form)
- Amlodipine Maleate (has salt form)
- Amlodipine Benzoate (active moiety of)
- Amlodipine mesylate (is active moiety of)
- Amlodipine camsylate (is active moiety of)
- Amlodipine besylate dihydrate (is active moiety of)
- Amlodipine mesylate monohydrate (is active moiety of)
- Amlodipine; hydrochlorothiazide; olmesartan medoxomil (component of)
Use (kg; approx.) in Germany (2009): >7500
Use (kg) in USA (2002): 7610
Use (kg) in France (2004): 2013
Consumption (g per capita; approx.) in Germany (2009): 0.0916
Consumption (g per capita) in the USA (2002): 0.027
Consumption (g per capita) in France (2004): 0.0333
Excretion rate: 0.38
Calculated removal (%): 30.4
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
H314 (33.3%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]
H318 (66.7%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
H341 (33.3%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]
H373 (66.7%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]
H400 (66.7%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]
H410 (66.7%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]
H411 (33.3%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]
P203, P260, P264, P264+P265, P270, P273, P280, P301+P316, P301+P330+P331, P302+P361+P354, P304+P340, P305+P354+P338, P316, P317, P318, P319, P321, P330, P363, P391, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Acute Tox. 3 (100%)
Eye Dam. 1 (66.7%)
STOT RE 2 (66.7%)
Aquatic Acute 1 (66.7%)
Aquatic Chronic 1 (66.7%)
Acute Tox. 3 (100%)
Skin Irrit. 2 (25%)
Eye Dam. 1 (100%)
STOT RE 2 (100%)
Aquatic Acute 1 (100%)
Aquatic Chronic 1 (100%)
Chronic therapy with amlodipine is associated with a low rate of serum enzyme elevations at rates that are similar to matched control populations. The enzyme elevations are usually mild, transient and asymptomatic and may resolve even during continued therapy. Clinically apparent liver injury from amlodipine is rare and described only in isolated case reports. In the few idiosyncratic cases reported, the latency period to onset of liver injury was usually 4 to 12 weeks, but examples with prolonged latency have also been published (10 months and several years). The latency period is shorter with recurrence on reexposure, including several instances of recurrence after liver injury due to other calcium channel blockers. The pattern of serum enzyme elevations is usually mixed or cholestatic. Rash, fever and eosinophilia have not been described and autoantibodies are not typical.
Likelihood score: C (probable but rare cause of clinically apparent liver injury).
M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007
M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
◉ Summary of Use during Lactation
Limited information indicates that milk levels of amlodipine are usually low and plasma levels in breastfed infants are undetectable. Maternal use of amlodipine during breastfeeding has not caused any adverse effects in breastfed infants. If the mother requires amlodipine, it is not a reason to discontinue breastfeeding.
◉ Effects in Breastfed Infants
A woman took amlodipine for hypertension 5 mg daily beginning 2 weeks postpartum. Her exclusively breastfed infant was examined regularly and at 3 months of age was healthy and had normal physical and neurological development.
One woman received amlodipine 2.5 mg orally twice daily during pregnancy for hypertension associated with glomerulonephritis. The dose was increased to 5 mg twice daily on day 2 postpartum. Her exclusively breastfed infant's growth was normal throughout the first year of life and no adverse effects were noted.
A preterm infant of 32 weeks gestation was breastfed exclusively from day 7 to day 20 postpartum. The infant's mother was taking amlodipine and labetalol in unspecified dosages for hypertension. The infant had apnea episodes unrelated to amlodipine. Growth at 2 months of age was slightly low.
Thirty-one women with pregnancy-induced hypertension postpartum received amlodipine 5 mg daily by mouth, with the dosage increased as needed to maintain blood pressure of 140/90 mm Hg or less. Their breastfed (extent not stated) infants exhibited no observed adverse cardiovascular effects within 3 weeks postpartum, although exact measurement methods were not stated.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
- CA2170278
- US6162802
- US5969156
- US6294197
- US5559111
- US6395728
- US6828339
- US5616599
- US6455574
- US8101599
- US8475839
- US8613949
- US8618174
- US8183295
- US7846961
- US6696481
- US9662315
- US10350171
- US10695329
- US9408837
- US10799453
- US10894039
- US10925835
- US10952998
- US10945960
- US10959991
- US11253474
- US11364230
- US11458095
- US11471409
- US11484498
- US11701326
- US11723866
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=HTIQEAQVCYTUBX-UHFFFAOYSA-N
- Avoid grapefruit products.
- Avoid natural licorice.
- Take with or without food. The absorption is unaffected by food.
- BindingDBLICENSEAll data curated by BindingDB staff are provided under the Creative Commons Attribution 3.0 License (https://creativecommons.org/licenses/by/3.0/us/).https://www.bindingdb.org/rwd/bind/info.jsp
- Comparative Toxicogenomics Database (CTD)LICENSEIt is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.http://ctdbase.org/about/legal.jsp
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useAmlodipinehttps://www.drugbank.ca/drugs/DB00381
- IUPHAR/BPS Guide to PHARMACOLOGYLICENSEThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)https://www.guidetopharmacology.org/about.jsp#licenseGuide to Pharmacology Target Classificationhttps://www.guidetopharmacology.org/targets.jsp
- Therapeutic Target Database (TTD)Amlodipine/ irbesartan fixed-dose combinationhttps://idrblab.net/ttd/data/drug/details/D02NZO
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/
- ChemIDplusAmlodipine [INN:BAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0088150429ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- EPA DSSToxCompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-notice3-ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylatehttps://chem.echa.europa.eu/100.102.4283,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl esterhttps://echa.europa.eu/substance-information/-/substanceinfo/100.125.8443,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (EC: 618-119-7)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/976103-ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate (EC: 425-820-1)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/111819
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Hazardous Substances Data Bank (HSDB)
- Human Metabolome Database (HMDB)LICENSEHMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.http://www.hmdb.ca/citingHMDB0005018_msms_441085https://hmdb.ca/metabolites/HMDB0005018#spectra
- New Zealand Environmental Protection Authority (EPA)LICENSEThis work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International licence.https://www.epa.govt.nz/about-this-site/general-copyright-statement/
- CCSbaseCCSbase Classificationhttps://ccsbase.net/
- ChEBI
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Pharmacological Classificationhttps://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
- LiverTox
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licence
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- DailyMed
- Drug Induced Liver Injury Rank (DILIrank) DatasetLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- European Medicines Agency (EMA)LICENSEInformation on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.https://www.ema.europa.eu/en/about-us/legal-noticeLodipressin (EMEA/V/C/003786)https://www.ema.europa.eu/en/medicines/veterinary/EPAR/lodipressin
- Drugs and Lactation Database (LactMed)
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/AMLODIPINENORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- WHO Model Lists of Essential MedicinesLICENSEPermission from WHO is not required for the use of WHO materials issued under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Intergovernmental Organization (CC BY-NC-SA 3.0 IGO) license.https://www.who.int/about/policies/publishing/copyright
- EU Clinical Trials Register
- Hazardous Chemical Information System (HCIS), Safe Work Australia
- Regulation (EC) No 1272/2008 of the European Parliament and of the CouncilLICENSEThe copyright for the editorial content of this source, the summaries of EU legislation and the consolidated texts, which is owned by the EU, is licensed under the Creative Commons Attribution 4.0 International licence.https://eur-lex.europa.eu/content/legal-notice/legal-notice.html3-ethyl 5-methyl...https://eur-lex.europa.eu/eli/reg/2008/1272/oj
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- NIST Mass Spectrometry Data CenterLICENSEData covered by the Standard Reference Data Act of 1968 as amended.https://www.nist.gov/srd/public-lawAmlodipinehttp://www.nist.gov/srd/nist1a.cfm
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.keg
- MassBank Europe
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- Metabolomics Workbench
- NIPH Clinical Trials Search of Japan
- SpectraBaseAmlodipine besylate breakdownhttps://spectrabase.com/spectrum/KnIno72CxOUAmlodipine besylate breakdownhttps://spectrabase.com/spectrum/20fVinVpQjsAMLODIPINE;3-ETHYL-5-METHYL-2-[2-(AMINOETHOXYMETHYL)-4-(2-CHLOROPHENYL)-1,4-DIHYDRO-6-METHYL-3,5-PYRIDINE-DICARBOXYLATEhttps://spectrabase.com/spectrum/KLPlDiH4OYw
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
- PharmGKBLICENSEPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).https://www.pharmgkb.org/page/policies
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/about
- Protein Data Bank in Europe (PDBe)
- Springer Nature
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- Wikidataamlodipinehttps://www.wikidata.org/wiki/Q411347
- WikipediaAmlodipinehttps://en.wikipedia.org/wiki/Amlodipine
- Wiley
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlAntihypertensive Agentshttps://www.ncbi.nlm.nih.gov/mesh/68000959Vasodilator Agentshttps://www.ncbi.nlm.nih.gov/mesh/68014665Calcium Channel Blockershttps://www.ncbi.nlm.nih.gov/mesh/68002121
- PubChem
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- EPA Substance Registry ServicesEPA SRS List Classificationhttps://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 403561222https://pubchem.ncbi.nlm.nih.gov/substance/403561222
- NCBI